Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.34% | -5.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.34% | -5.16% | |||
| Cost of Revenue | -4.13% | -16.15% | |||
| Gross Profit | 11.12% | 3.09% | |||
| SG&A Expenses | -12.52% | -25.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.72% | -21.54% | |||
| Operating Income | 98.86% | 344.66% | |||
| Income Before Tax | 53.50% | 287.62% | |||
| Income Tax Expenses | -192,781.82% | -- | |||
| Earnings from Continuing Operations | 2,150.45% | 289.68% | |||
| Earnings from Discontinued Operations | 5.00% | 6.54% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2,387.05% | 242.34% | |||
| EBIT | 98.86% | 344.66% | |||
| EBITDA | 90.68% | 442.23% | |||
| EPS Basic | 2,384.51% | 242.29% | |||
| Normalized Basic EPS | 123.37% | 287.52% | |||
| EPS Diluted | 2,142.58% | 125.16% | |||
| Normalized Diluted EPS | 123.01% | 130.01% | |||
| Average Basic Shares Outstanding | 0.09% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.04% | 526.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||